Rosemary Akhurst

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc TGF-beta antagonists: why suppress a tumor suppressor?
    Rosemary J Akhurst
    University of California San Francisco, Mount Zion Cancer Research Institute, Room S231, Box 0875, 2340 Sutter Street, San Francisco, California 94143 0875, USA
    J Clin Invest 109:1533-6. 2002
  2. ncbi request reprint TGF beta signaling in health and disease
    Rosemary J Akhurst
    Nat Genet 36:790-2. 2004
  3. ncbi request reprint TGF beta inhibition for cancer therapy
    Elise F Saunier
    Mount Zion Cancer Research Institute and UCSF Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 0875, USA
    Curr Cancer Drug Targets 6:565-78. 2006
  4. pmc Complexities of TGF-β targeted cancer therapy
    Erin C Connolly
    UCSF Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, California 94143 0512, USA
    Int J Biol Sci 8:964-78. 2012
  5. pmc Targeting the TGFβ signalling pathway in disease
    Rosemary J Akhurst
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94158, USA
    Nat Rev Drug Discov 11:790-811. 2012
  6. pmc The complexities of TGF-β action during mammary and squamous cell carcinogenesis
    Erin C Connolly
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, California 94143 0512, USA
    Curr Pharm Biotechnol 12:2138-49. 2011
  7. pmc Transforming growth factor-beta in breast cancer: too much, too late
    Mary Helen Barcellos-Hoff
    New York University Langone School of Medicine, New York, NY 10016, USA
    Breast Cancer Res 11:202. 2009
  8. ncbi request reprint Large- and small-molecule inhibitors of transforming growth factor-beta signaling
    Rosemary J Akhurst
    University of California at San Francisco, P O Box 0875, Cancer Research Institute, 2340 Sutter Street, San Francisco, CA 94143 0875, USA
    Curr Opin Investig Drugs 7:513-21. 2006
  9. ncbi request reprint TGF-beta signaling in cancer--a double-edged sword
    R J Akhurst
    Mt Zion Cancer Research Institute, University of California at San Francisco, San Francisco, CA 94143 0875, USA
    Trends Cell Biol 11:S44-51. 2001
  10. ncbi request reprint Differentiation plasticity regulated by TGF-beta family proteins in development and disease
    Rik Derynck
    Department of Cell and Tissue Biology, Program in Cell Biology, University of California San Francisco, San Francisco, CA 94143 0512, USA
    Nat Cell Biol 9:1000-4. 2007

Collaborators

  • Jian Hua Mao
  • RIK M DERYNCK
  • Jesus Perez-Losada
  • WOLFGANG KORN
  • Mary Helen Barcellos-Hoff
  • Jong Seok Kang
  • A Balmain
  • Erin C Connolly
  • Kelly A Harradine
  • Elise F Saunier
  • Yang Tang
  • Martin Oft
  • Markus D Lacher
  • Ellen Poon
  • Margaret L McKinnon
  • Susana Wang
  • Kenneth B Ewan
  • Julia Freimuth
  • Ervin H Epstein
  • Boris C Bastian
  • Dan H Moore
  • Katie Ridd
  • Frederic F Clermont
  • Meri T Firpo
  • Christine Christian
  • Maarit I Tiirikainen
  • Mario Anders
  • Frederic Clermont
  • Alison Condie
  • Kyeong Sook Lee
  • Darren W Logan
  • Liam J Holt
  • Minh Thu Luu
  • HaiTao Yang
  • Li Ming Leong
  • Sarah A B Rusholme
  • Maria Jose Pajares
  • M H Barcellos Hoff
  • Rhonda L Henshall-Powell
  • Shraddha A Ravani
  • Ray Warters
  • Carlos Arteaga

Detail Information

Publications22

  1. pmc TGF-beta antagonists: why suppress a tumor suppressor?
    Rosemary J Akhurst
    University of California San Francisco, Mount Zion Cancer Research Institute, Room S231, Box 0875, 2340 Sutter Street, San Francisco, California 94143 0875, USA
    J Clin Invest 109:1533-6. 2002
  2. ncbi request reprint TGF beta signaling in health and disease
    Rosemary J Akhurst
    Nat Genet 36:790-2. 2004
  3. ncbi request reprint TGF beta inhibition for cancer therapy
    Elise F Saunier
    Mount Zion Cancer Research Institute and UCSF Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 0875, USA
    Curr Cancer Drug Targets 6:565-78. 2006
    ..This review discusses the progress made in the pre-clinical and clinical testing of TGFbeta inhibitors, and discusses considerations of target populations and potential drug regimens...
  4. pmc Complexities of TGF-β targeted cancer therapy
    Erin C Connolly
    UCSF Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, California 94143 0512, USA
    Int J Biol Sci 8:964-78. 2012
    ..Current paradigms for the use of TGF-β inhibitors in oncology have therefore moved towards the use of combinatorial therapies and short term dosing, with considerable promise for the clinic...
  5. pmc Targeting the TGFβ signalling pathway in disease
    Rosemary J Akhurst
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94158, USA
    Nat Rev Drug Discov 11:790-811. 2012
    ....
  6. pmc The complexities of TGF-β action during mammary and squamous cell carcinogenesis
    Erin C Connolly
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, California 94143 0512, USA
    Curr Pharm Biotechnol 12:2138-49. 2011
    ..This review also discusses the role TGF-β within the tumor microenvironment particularly its ability to polarize the microenvironment towards a pro-tumorigenic milieu...
  7. pmc Transforming growth factor-beta in breast cancer: too much, too late
    Mary Helen Barcellos-Hoff
    New York University Langone School of Medicine, New York, NY 10016, USA
    Breast Cancer Res 11:202. 2009
    ..Too much TGFbeta, too late in cancer progression is the fundamental motivation for pharmaceutical inhibition...
  8. ncbi request reprint Large- and small-molecule inhibitors of transforming growth factor-beta signaling
    Rosemary J Akhurst
    University of California at San Francisco, P O Box 0875, Cancer Research Institute, 2340 Sutter Street, San Francisco, CA 94143 0875, USA
    Curr Opin Investig Drugs 7:513-21. 2006
    ..A deeper understanding of these issues will assist in targeting the right patients for such therapy, and in limiting unwanted side effects...
  9. ncbi request reprint TGF-beta signaling in cancer--a double-edged sword
    R J Akhurst
    Mt Zion Cancer Research Institute, University of California at San Francisco, San Francisco, CA 94143 0875, USA
    Trends Cell Biol 11:S44-51. 2001
    ..Therapeutic approaches should aim to inhibit the TGF-beta-induced invasive phenotype, but also to retain its growth-inhibitory and apoptosis-inducing effects...
  10. ncbi request reprint Differentiation plasticity regulated by TGF-beta family proteins in development and disease
    Rik Derynck
    Department of Cell and Tissue Biology, Program in Cell Biology, University of California San Francisco, San Francisco, CA 94143 0512, USA
    Nat Cell Biol 9:1000-4. 2007
    ..Hence, various pathologies in adults may be considered diseases of abnormal development and differentiation...
  11. ncbi request reprint TGFbeta inhibition of yolk-sac-like differentiation of human embryonic stem-cell-derived embryoid bodies illustrates differences between early mouse and human development
    Ellen Poon
    Cancer Research Institute, Comprehensive Cancer Center, University of California San Francisco, Box 0875, 2340 Sutter Street, Room S231, San Francisco, CA 94143, USA
    J Cell Sci 119:759-68. 2006
    ..This study highlights important differences between early human and mouse embryonic development and suggests a role of TGFbeta in human hypoblast differentiation...
  12. ncbi request reprint Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition
    Markus D Lacher
    Division of Gastroenterology and Hematology Oncology, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94143, USA
    Cancer Res 66:1648-57. 2006
    ..These findings show down-regulation of CAR in the context of EMT and suggest that combination of therapeutic adenoviruses and TGF-beta receptor inhibitors could be an efficient anticancer strategy...
  13. ncbi request reprint Metastasis is driven by sequential elevation of H-ras and Smad2 levels
    Martin Oft
    University of California at San Francisco Comprehensive Cancer Center, Box 0875, San Francisco, California 94143 0875, USA
    Nat Cell Biol 4:487-94. 2002
    ..These findings have far-reaching implications for the prevention of tumour growth, invasion and metastasis...
  14. ncbi request reprint Epistatic interactions between modifier genes confer strain-specific redundancy for Tgfb1 in developmental angiogenesis
    Yang Tang
    Mt Zion Cancer Research Institute, University of California, San Francisco, Box 0875, 2340 Sutter Street, Room S231, San Francisco, CA 94143, USA
    Genomics 85:60-70. 2005
    ..Identification of angiogenesis-modifying genes may provide new targets for angiogenesis therapies and analysis of polymorphisms therein may contribute to assessment of risk for diseases involving angiogenesis...
  15. pmc Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients
    Kelly A Harradine
    UCSF Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California, USA
    Clin Cancer Res 15:5101-7. 2009
    ..This study investigates whether TGF-beta signaling is elevated in transplant patients...
  16. ncbi request reprint Mutations of TGFbeta signaling molecules in human disease
    Kelly A Harradine
    Cancer Research Institute, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Ann Med 38:403-14. 2006
    ..In this respect, genetic background might be a central factor in determining disease outcome and treatment strategy for TGFbeta-associated diseases...
  17. pmc Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility
    Jian Hua Mao
    Cancer Research Institute, Comprehensive Cancer Center, Department of Biochemistry, University of California, San Francisco, CA 94143 0875, USA
    Proc Natl Acad Sci U S A 103:8125-30. 2006
    ..These findings illustrate the power of complex genetic interactions in determining disease outcome and have major implications to the assessment of disease risk in individuals harboring variant TGFB1 alleles...
  18. ncbi request reprint Genetic modifiers interact with maternal determinants in vascular development of Tgfb1(-/-) mice
    Yang Tang
    UCSF Mt Zion Cancer Research Institute, Box 0875, 2340 Sutter Street, San Francisco, CA 94143, USA
    Hum Mol Genet 12:1579-89. 2003
    ..Molecular identification of the functional gene(s) encoding Tgfbkm2 and its interacting maternal factors will be central to an understanding of the mode of action of TGFbeta1 in cardiovascular development...
  19. pmc The type I TGF-beta receptor is covalently modified and regulated by sumoylation
    Jong Seok Kang
    Department of Cell and Tissue Biology, Program in Cell Biology, University of California San Francisco, California 94143, USA
    Nat Cell Biol 10:654-64. 2008
    ..T beta RI sumoylation therefore controls responsiveness to TGF-beta, with implications for tumour progression. Sumoylation of cell-surface receptors may regulate other growth factor responses...
  20. ncbi request reprint Transforming growth factor-beta1 mediates cellular response to DNA damage in situ
    Kenneth B Ewan
    Lawrence Berkeley National Laboratory, University of California, Berkeley 94720, USA
    Cancer Res 62:5627-31. 2002
    ..These data indicate that TGF-beta1 is essential for rapid p53-mediated cellular responses that mediate cell fate decisions in situ...
  21. ncbi request reprint Cancer: dangerous liaisons
    Allan Balmain
    Nature 428:271-2. 2004
  22. ncbi request reprint A sweet link between TGFbeta and vascular disease?
    Rosemary J Akhurst
    Nat Genet 38:400-1. 2006

Research Grants18

  1. GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO
    Rosemary Akhurst; Fiscal Year: 2001
    ..Identity of tgfmod1 will be confirmed by genotype/phenotype correlation in several mouse strains, and by functional analysis, including transgenesis. ..
  2. "Genetic interactions between Tgfb1 and Skts15/Tgfbm3 in cancer"
    Rosemary J Akhurst; Fiscal Year: 2010
    ..for assessment of cancer risk in humans c) May provide new targets or indicate certain combinatorial targets for anti-cancer drug development d) May contribute to design of personalized medicines for anti-TGFbeta cancer therapies ..
  3. "Genetic interactions between Tgfb1 and Skts15/Tgfbm3 in cancer"
    Rosemary Akhurst; Fiscal Year: 2009
    ..for assessment of cancer risk in humans c) May provide new targets or indicate certain combinatorial targets for anti-cancer drug development d) May contribute to design of personalized medicines for anti-TGFbeta cancer therapies ..
  4. Functional analysis of Tgfbm3 locus in vascular development and disease
    Rosemary Akhurst; Fiscal Year: 2009
    ..assessment of disease risk in ailments known to have a TGFB1 associationc) Will provide targets for prophylactic drug development of such diseases d) May provide predictive markers for response to anti-TGFb drug therapies ..
  5. "Genetic interactions between Tgfb1 and Skts15/Tgfbm3 in cancer"
    Rosemary Akhurst; Fiscal Year: 2007
    ..tools for assessment of cancer risk in humans c) May provide new targets or indicate certain combinatorial targets for anti-cancer drug development d) May contribute to design of personalized medicines for anti-TGFbeta cancer therapies ..
  6. Functional analysis of Tgfbm3 locus in vascular development and disease
    Rosemary Akhurst; Fiscal Year: 2006
    ..tools for assessment of disease risk in ailments known to have a TGFB1 associationc) Will provide targets for prophylactic drug development of such diseases d) May provide predictive markers for response to anti-TGFb drug therapies ..
  7. GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO
    Rosemary Akhurst; Fiscal Year: 2004
    ..Identity of tgfmod1 will be confirmed by genotype/phenotype correlation in several mouse strains, and by functional analysis, including transgenesis. ..
  8. Functional analysis of Tgfbm3 locus in vascular development and disease
    Rosemary J Akhurst; Fiscal Year: 2010
    ..assessment of disease risk in ailments known to have a TGFB1 associationc) Will provide targets for prophylactic drug development of such diseases d) May provide predictive markers for response to anti-TGFb drug therapies ..
  9. GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO
    Rosemary Akhurst; Fiscal Year: 2002
    ..Identity of tgfmod1 will be confirmed by genotype/phenotype correlation in several mouse strains, and by functional analysis, including transgenesis. ..
  10. TGFBM2 in Development and Disease
    Rosemary Akhurst; Fiscal Year: 2009
    ..We have identified a gene that interacts with TGFB1 in mice and humans to alter vascular disease progression. Understanding how these molecules interact may ultimately help to design new or better drugs. ..
  11. GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO
    Rosemary Akhurst; Fiscal Year: 2003
    ..Identity of tgfmod1 will be confirmed by genotype/phenotype correlation in several mouse strains, and by functional analysis, including transgenesis. ..
  12. GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO
    Rosemary Akhurst; Fiscal Year: 2004
    ..Identity of tgfmod1 will be confirmed by genotype/phenotype correlation in several mouse strains, and by functional analysis, including transgenesis. ..
  13. GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO
    Rosemary Akhurst; Fiscal Year: 2003
    ..Identity of tgfmod1 will be confirmed by genotype/phenotype correlation in several mouse strains, and by functional analysis, including transgenesis. ..
  14. GENETIC MODIFIERS OF TGF BETA 1 ACTION IN VIVO
    Rosemary Akhurst; Fiscal Year: 2004
    ..Identity of tgfmod1 will be confirmed by genotype/phenotype correlation in several mouse strains, and by functional analysis, including transgenesis. ..
  15. Functional analysis of Tgfbm3 locus in vascular development and disease
    Rosemary Akhurst; Fiscal Year: 2007
    ..tools for assessment of disease risk in ailments known to have a TGFB1 associationc) Will provide targets for prophylactic drug development of such diseases d) May provide predictive markers for response to anti-TGFb drug therapies ..
  16. TGFBM2 in Development and Disease
    Rosemary J Akhurst; Fiscal Year: 2010
    ..We have identified a gene that interacts with TGFB1 in mice and humans to alter vascular disease progression. Understanding how these molecules interact may ultimately help to design new or better drugs. ..